Cantor Fitzgerald Comments on CMPS FY2025 Earnings

COMPASS Pathways plc (NASDAQ:CMPS) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of COMPASS Pathways in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings of ($2.05) per share for the year. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.

Several other equities analysts have also recently issued reports on CMPS. HC Wainwright lowered their price objective on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Maxim Group lowered their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $33.60.

COMPASS Pathways Trading Up 3.8 %

NASDAQ CMPS opened at $3.87 on Wednesday. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The stock’s fifty day moving average price is $4.19 and its 200-day moving average price is $5.80. The stock has a market cap of $264.79 million, a P/E ratio of -1.76 and a beta of 2.27. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the previous year, the company earned ($0.67) earnings per share.

Institutional Investors Weigh In On COMPASS Pathways

A number of hedge funds have recently bought and sold shares of CMPS. Flagship Harbor Advisors LLC bought a new position in shares of COMPASS Pathways in the 4th quarter valued at about $43,000. Green Alpha Advisors LLC purchased a new position in COMPASS Pathways during the 3rd quarter valued at $99,000. Y Intercept Hong Kong Ltd bought a new stake in COMPASS Pathways during the 3rd quarter valued at about $131,000. Geode Capital Management LLC raised its position in COMPASS Pathways by 160.3% during the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after purchasing an additional 25,970 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in COMPASS Pathways in the third quarter worth about $371,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.